Research field (6)：
Dermatology
, Respiratory surgery
, Cardiovascular surgery
, Other
, Respiratory medicine
, Biological, health, and medical informatics
2023 - 2027 Development of a novel therapeutic strategy targeting the microenvironment that tolerates the progression of refractory lung cancer
2023 - 2027 Functional analysis of TLS, tumor-infiltrating B-cell, by spatial multi-omics profiling and its application to tumor immunotherapy
2023 - 2026 メタゲノム解析によるCOPD合併肺がんの臓器横断的ディスバイオーシスの解明
2023 - 2026 Elucidation of Tumor Microenvironment Network Regulated by Fibrinolysis Inhibitory Factor and Its Therapeutic Application
2023 - 2026 Identification of genetic loci associated with chronic lung allograft dysfunction after lung transplantation using an ethnic-specific single-nucleotide polymorphism array
2022 - 2026 マトリセルラータンパク質阻害によるがん微小環境の破壊と抗腫瘍効果の検討
2022 - 2026 マトリセルラータンパク質阻害によるがん微小環境の破壊と抗腫瘍効果の検討
2022 - 2025 Clarification of the mechanism for endogenous retrovirus to get involved in the antitumor immunity response
2021 - 2024 Exploration of the novel therapeutic target for lung cancer based on the analysis of the characteristics of tumor cells derived from 3D culture
2020 - 2023 Development of next-generation precision medicine targeting the pathways on which driver gene mutation-positive lung cancer depends
2019 - 2023 基底膜構成分子の誘導制御による低侵襲角化歯肉獲得療法の確立
2019 - 2023 腫瘍免疫活性化遺伝子REICによる肺癌の革新的免疫療法の開発
2019 - 2022 Development of a new treatment strategy for HER2-alterated lung cancer
2019 - 2022 Development of the novel therapy focused on damage-associated molecular patterns (DAMPs) for lung fibrosis-related diseases
2019 - 2022 Immune related gene-expression profiling for the combination of chemotherapy and PD-1/PD-L1 inhibition.
2019 - 2022 Novel treatment strategy for malignant pleural mesothelioma targeting the tumor stem cell marker DCLK1
2018 - 2021 Development of innovative therapeutic antibodies targeting the inflammatory tumor microenvironment in refractory thoracic tumors
2018 - 2021 Novel therapeutic strategy focused on EGFR-binding protein LRIG1 for EGFR-mutant lung cancer
2017 - 2021 Comprehensive analysis of exosomes in cartilage and approach to the new strategy for osteoarthritis therapy
2017 - 2020 Mechanistic analysis of an unidentified downstream signals of S100A8/A9 receptors that play a crucial role in acquisition of metastatic force and formation of cancer microenvironment.
2017 - 2020 分子バーコードを用いた高感度遺伝子変異解析と機能解析
2017 - 2019 Identification of marker genes and pathways specific to precancerous duodenal adenomas and early stage adenocarcinomas.
2016 - 2019 Novel therapeutic method for HER2 active cancer focusing on HER2 novel binding molecule cytokeratin 19
2016 - 2019 Molecular targeted therapy against adenocarcinoma of the lung harboring MET exon 14 skipping mutation
2016 - 2019 Development of new therapeutic strategy based on gene expression and mutation profiles in EGFR mutant lung cancer
2003 - 2005 Integrated system of the tailor-made cancer treatment based on the expression profiling and bioinformatic analyses
2000 - 2004 Multifaceted analysis of molecular pathogenesis of human lung cancers
Show all
Papers (123)：
Kiichiro Ninomiya, Daisuke Ennishi, Kunio Okamoto, Midori Ando, Satoko Nakamura, Shuta Tomida, Yoshiyuki Ayada, Go Makimoto, Eiki Ichihara, Natsuko Okita, et al. Response to Imatinib in a Patient With Gastric Adenocarcinoma With KIT Q556_K558 In-Frame Deletion: A Case Report. JCO precision oncology. 2024. 8. e2400228
Minori Sasakura, Hitoshi Urakami, Kota Tachibana, Kenta Ikeda, Ken-Ichi Hasui, Yoshihiro Matsuda, Ko Sunagawa, Daisuke Ennishi, Shuta Tomida, Shin Morizane. Topical application of activator protein-1 inhibitor T-5224 suppresses inflammation and improves skin barrier function in a murine atopic dermatitis-like dermatitis. Allergology international : official journal of the Japanese Society of Allergology. 2024. 73. 2. 323-331
Hidetoshi Hayashi, Kenji Chamoto, Ryusuke Hatae, Takashi Kurosaki, Yosuke Togashi, Kazuya Fukuoka, Megumi Goto, Yasutaka Chiba, Shuta Tomida, Takayo Ota, et al. Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade. Journal of Clinical Investigation. 2024. 134. 7
